behavioral

BRD-6929 is a selective, brain-penetrant HDAC1 and HDAC2 inhibitor (IC50:  1 and 8 nM). BRD-6929 (Cpd-60) shows high-affinity to HDAC1 and HDAC2 (Kis: 0.2 and 1.5 nM) [2]. BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV

PD184161 is a novel, orally-active MEK inhibitor. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner[1].

Eticlopride, an antipsychotic, is a Selective dopamine D2/D3 receptor antagonist (Ki: 0.5/0.16 nM).

Tocofersolan (TPGS) is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of Tocopherol. Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis.

BTRX-335140 (CYM-53093) is a potent and selective orally active κ-opioid receptor (KOR) antagonist with antagonistic activity against κOR, μOR, and δOR with IC50 values of 0.8, 110, and 6500 nM, respectively.

PAOPA belongs to natural product derivatives and serves as an allosteric modulator of the dopamine D2 receptor, possessing the characteristic of promoting binding between high-affinity D2 receptors and agonists. This compound finds application in preclinical studies for schizophrenia and extrapyramidal dysfunction, effectively alleviating behavioral and biochemical abnormalities in rodent models.

Milenperone (R 34009) is a novel anti-invasive compound designed to control behavioral disorders in patients with epilepsy and alcoholism.

Divaplon is a GABA receptor agonist (IC50: 0.056 µM) that exhibits non-sedating anxiolytic properties in a rat model of anxiety.

Lecozotan HCl (SRA-333) is a potent and selective 5-HT antagonist that significantly enhances KCl-stimulated glutamate and acetylcholine release from the hippocampal dentate gyrus and has cognitive enhancing properties. Chronic administration of Lecozotan HCl did not induce 5-HT(1A) receptor tolerance or desensitization in a behavioral model demonstrating 5-HT(1A) receptor function.

Ordopidine (ACR325) is a dopaminergic stabilizer that suppresses psychostimulant-induced hyperactivity disorder and stimulates behavior during inactivity. Ordopidine acts as a dopamine D2 receptor antagonist in vitro and, despite its low affinity, its specific state-dependent behavioral effect characteristics are not generally shared by D2 receptor antagonists.

Fezolamine is a novel orally available non-tricyclic compound with antidepressant activity. It is three to two times more selective in blocking synaptosomal uptake of [3H]norepinephrine than uptake of [4H]3-hydroxytryptamine or [3H]dopamine in vitro. It blocked the inhibitory effects of rifampicin and tetraphenyl in classical behavioral tests using monoamine-depleted animals.

Gevotroline, a chemical in palm wine that can be used to treat psychosis, is a 5-HT2 receptor antagonist that can be used to study behavioral disorders.

3,4,5-Trimethoxybenzoic acid (Gallic acid trimethyl ether) are potent antioxidants and inhibitor of cytokine production. It can ameliorate chronic stress-induced various behavioral and biochemical alterations in mice. It also exerts hepatoprotective effects in CCl4-induced rats, specifically by modulating oxidative-nitrosative stress and inflammation.

HEPPS exhibits inhibitory activity against the amyloid-beta precursor protein, reducing Aβ aggregation burden and improving neuronal autophagy flux, thereby alleviating neuronal apoptosis and traumatic brain injury (TBI) in mice. It can be used for research into Alzheimer's disease and neurological disorders.

3-Methoxytyramine (3-O-methyl Dopamine) is a cellular metabolite of dopamine (3-hydroxytyramine), a neuromodulator that induces behavioral effects, induces significant ERK and CREB phosphorylation, and is capable of inducing a complex set of aberrant involuntary movements in acutely depleted dopamine-containing mice.

(±)-Myrtenol is the specific enantiomeric form of the bicyclic monoterpene alcohol known as Myrtenol. (-)-Myrtenol has been demonstrated to possess significant anti-anxiety effects in preclinical behavioral models; additionally, (-)-Myrtenol exhibits characteristics of gastric cell protection, suggesting potential therapeutic applications for gastrointestinal conditions.

LSP4-2022 is a selective, blood-brain barrier-permeable mGlu4 orthosteric agonist (EC50 = 0.11 μM) capable of inhibiting neurotransmission in wild-type mouse cerebellar slices, exhibiting pro-depressive activity.

p-Ethynylphenylalanine hydrochloride (4-Ethynyl-L-phenylalanine HCL) is a novel, potent, and specific inhibitor of TPH[1]. Its potential to selectively and reversibly inhibit serotonin biosynthesis may contribute to characterizing the role of serotonin in behavioral and physiological activities[1].

Butyrolactone II (A9) exhibits DPPH radical scavenging activity with an EC50 value of 42.05 μM, superior to the positive control BHT. Butyrolactone II (A9) demonstrates neuroprotective activity in Caenorhabditis elegans CL2355 by alleviating Aβ-induced chemotaxis disorder, prolonging lifespan, and reducing 5-HT sensitivity, and is utilized in neurodegeneration research focused on oxidative stress mitigation, amyloid-associated functional impairment, and behavioral phenotype modulation in nematode models.

Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABAA receptor. Imidazoleacetic acid is generated through histamine oxidation in the mouse brain and exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces centrally mediated responses including analgesia, sedation, hypnosis, and reductions in blood pressure, body temperature, isolation-induced aggression, and motor activity. Imidazoleacetic acid is valuable for neuropharmacology and neurotransmitter signaling investigations involving histaminergic and GABAergic pathways.

Ro 41-1049 hydrochloride is a potent, selective, and reversible inhibitor of monoamine oxidase-A (MAO-A). Ro 41-1049 hydrochloride binds MAO-A with high affinity and is frequently used in neuropharmacology research to investigate MAO-A-mediated neurotransmitter metabolism and related behavioral effects.

AAZ-A 154 hydrobromide is a selective, competitive, non-hallucinogenic 5-HT2AR antagonist. It promotes neuronal growth in rodents and yields enduring beneficial behavioral effects.

AAZ-A 154 mesylate mesylate is a selective, competitive, and non-hallucinogenic antagonist of 5-HT2AR. It enhances neuronal growth in rodents and produces enduring beneficial behavioral effects.

AAZ-A 154 benzoate is a selective, competitive, and non-hallucinogenic 5-HT2AR antagonist. This compound facilitates neuronal growth in rodents and produces lasting beneficial behavioral effects.